Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

By A. Ferreri, J. Blay, M. Reni, F. Pasini, M. Spina, A. Ambrosetti, A. Calderoni, A. Rossi, V. Vavassori, A. Conconi and 13 more. Journal of Clinical Oncology, 2003

772 citations recorded by the source corpus.

Subfields: Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/5f49b8a3a0eda9965dbafca37fa8c69c0c1d99b0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Ferreri
2. M. Foppoli
3. M. Martelli
4. F. Caligaris‐cappio
5. M. Reni
6. G. Rossi
7. G. A. Pangalis
8. A. Brandes

Citations in the corpus

• High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. (2009, methodology): “Risk groups were defined according to the IELSG score.(24) Patients in whom lumbar puncture was contraindicated were considered as having an unfavourable feature for CSF protein concentration variable.”